S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
NASDAQ:STIM

Neuronetics (STIM) Stock Price, News & Analysis

$4.76
-0.04 (-0.83%)
(As of 03/28/2024 ET)
Today's Range
$4.64
$4.91
50-Day Range
$2.79
$4.80
52-Week Range
$1.03
$4.99
Volume
64,274 shs
Average Volume
199,160 shs
Market Capitalization
$141.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Neuronetics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
68.1% Upside
$8.00 Price Target
Short Interest
Healthy
0.18% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.55mentions of Neuronetics in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$519,307 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.92) to ($0.62) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.01 out of 5 stars

Medical Sector

410th out of 938 stocks

Surgical & Medical Instruments Industry

49th out of 95 stocks

STIM stock logo

About Neuronetics Stock (NASDAQ:STIM)

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

STIM Stock Price History

STIM Stock News Headlines

Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
STIM Apr 2024 5.000 put
Neuronetics Q4 2023 Earnings Preview
See More Headlines
Receive STIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/05/2024
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:STIM
Employees
203
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$8.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+68.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-30,190,000.00
Pretax Margin
-42.31%

Debt

Sales & Book Value

Annual Sales
$71.35 million
Book Value
$1.18 per share

Miscellaneous

Free Float
27,584,000
Market Cap
$141.66 million
Optionable
Optionable
Beta
2.38
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

STIM Stock Analysis - Frequently Asked Questions

Should I buy or sell Neuronetics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" STIM shares.
View STIM analyst ratings
or view top-rated stocks.

What is Neuronetics' stock price target for 2024?

2 analysts have issued 1-year price targets for Neuronetics' shares. Their STIM share price targets range from $8.00 to $8.00. On average, they expect the company's share price to reach $8.00 in the next year. This suggests a possible upside of 68.1% from the stock's current price.
View analysts price targets for STIM
or view top-rated stocks among Wall Street analysts.

How have STIM shares performed in 2024?

Neuronetics' stock was trading at $2.90 on January 1st, 2024. Since then, STIM shares have increased by 64.1% and is now trading at $4.76.
View the best growth stocks for 2024 here
.

Are investors shorting Neuronetics?

Neuronetics saw a decline in short interest during the month of March. As of March 15th, there was short interest totaling 53,200 shares, a decline of 64.9% from the February 29th total of 151,700 shares. Based on an average trading volume of 204,300 shares, the short-interest ratio is currently 0.3 days.
View Neuronetics' Short Interest
.

When is Neuronetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our STIM earnings forecast
.

How were Neuronetics' earnings last quarter?

Neuronetics, Inc. (NASDAQ:STIM) issued its quarterly earnings results on Tuesday, March, 5th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.26) by $0.07. The business earned $20.31 million during the quarter, compared to analysts' expectations of $19.73 million. Neuronetics had a negative trailing twelve-month return on equity of 72.76% and a negative net margin of 42.31%. During the same period in the previous year, the company posted ($0.30) earnings per share.

What guidance has Neuronetics issued on next quarter's earnings?

Neuronetics issued an update on its first quarter 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $16.7 million-$17.7 million, compared to the consensus revenue estimate of $17.0 million.

What other stocks do shareholders of Neuronetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Gilead Sciences (GILD), iBio (IBIO), Onconova Therapeutics (ONTX), Pfizer (PFE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT) and Acasti Pharma (ACST).

When did Neuronetics IPO?

Neuronetics (STIM) raised $75 million in an IPO on Thursday, June 28th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

Who are Neuronetics' major shareholders?

Neuronetics' stock is owned by many different retail and institutional investors. Top institutional investors include Cannell Capital LLC (9.57%), Balyasny Asset Management L.P. (4.90%), Kent Lake Capital LLC (3.86%), Millrace Asset Group Inc. (2.51%), Thompson Siegel & Walmsley LLC (0.65%) and Dimensional Fund Advisors LP (0.40%). Insiders that own company stock include Bruce Joseph Shook, Cannell Capital Llc, Keith J Sullivan, Paul Liberman, Robert Cascella, Sheryl L Conley, Stephen Furlong and William Andrew Macan.
View institutional ownership trends
.

How do I buy shares of Neuronetics?

Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:STIM) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners